VASOCIDIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VASOCIDIN (VASOCIDIN).
Vasocidin is a combination of sulfacetamide sodium, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking folate synthesis and bacterial growth, and prednisolone sodium phosphate, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and subsequent prostaglandin and leukotriene synthesis.
| Metabolism | Sulfacetamide is primarily metabolized via acetylation in the liver; prednisolone is metabolized via hepatic metabolism by cytochrome P450 enzymes (primarily CYP3A4) and reduction reactions. |
| Excretion | Renal: 70-80% as unchanged drug; biliary/fecal: 20-30% as metabolites and unchanged drug. |
| Half-life | Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment. |
| Protein binding | 20-30% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 0.2-0.3 L/kg; indicates distribution primarily into extracellular fluid. |
| Bioavailability | Ophthalmic: negligible systemic absorption (<5%) after topical administration. |
| Onset of Action | Ophthalmic: 15-30 minutes after topical administration. |
| Duration of Action | Ophthalmic: 4-6 hours; clinical effect may persist longer with repeated dosing. |
| Molecular Weight | Sulfacetamide: 214.24 Da; Prednisolone: 360.44 Da |
One drop of the ophthalmic suspension into the conjunctival sac of the affected eye(s) every 4 hours while awake and at bedtime for 7 days; duration may be extended based on clinical response.
| Dosage form | OINTMENT |
| Renal impairment | No specific guidelines for ophthalmic use; systemic absorption is minimal. For suspected systemic toxicity, adjust based on prednisolone and sulfacetamide components. |
| Liver impairment | No specific guidelines for ophthalmic use; systemic absorption is minimal. Use with caution in severe hepatic impairment due to potential corticosteroid effects. |
| Pediatric use | Children ≥2 years: one drop into affected eye(s) every 4 hours while awake and at bedtime for 7 days. Safety and efficacy in children <2 years not established. |
| Geriatric use | No specific dose adjustment required; use same dosing as adults. Monitor for increased intraocular pressure or delayed healing due to corticosteroid component. |
| 1st trimester | Avoid use; contains sulfonamide component which may increase risk of congenital malformations, particularly neural tube defects, during first trimester. |
| 2nd trimester | Use only if clearly needed; sulfonamides may cause kernicterus in premature infants. |
| 3rd trimester | Contraindicated; sulfonamides can cause kernicterus in neonates due to bilirubin displacement. |
Clinical note
Comprehensive clinical and safety monograph for VASOCIDIN (VASOCIDIN).
| Placental transfer | Both sulfacetamide and prednisolone are known to cross the placenta; sulfonamides achieve fetal plasma levels approximately 70-90% of maternal levels. |
| Breastfeeding | Sulfonamides are excreted into breast milk; avoid use in nursing mothers due to risk of kernicterus in infants with G6PD deficiency or hyperbilirubinemia. |
■ FDA Black Box Warning
Sulfonamides are associated with severe hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and fatalities; use caution in patients with known sulfonamide allergy.
| Serious Effects |
Hypersensitivity to sulfonamides or prednisoloneViral infections of the corneaFungal infections of the eyeOcular tuberculosisGlaucoma (for prednisolone component)
| Precautions | Prolonged use may lead to cataract formation, elevated intraocular pressure, glaucoma, and secondary ocular infections, Hypersensitivity reactions including anaphylaxis and skin reactions possible, May mask signs of bacterial, fungal, or viral infections, Not for injection; ophthalmic use only |
| Food/Dietary | No known food interactions with VASOCIDIN ophthalmic suspension. However, if taken orally (not indicated), neomycin may cause malabsorption. For ophthalmic use, no dietary restrictions are necessary, but maintaining overall hydration and a balanced diet supports eye health. |
Loading safety data…
| Lactation Rating |
| L4 - Possibly Hazardous |
| Teratogenic Risk | Pregnancy Category C. No adequate studies in pregnant women. In animal studies, corticosteroids have been shown to be teratogenic at high doses. Sulfacetamide may cause kernicterus if used near term due to displacement of bilirubin from albumin. Avoid use in pregnant women unless potential benefit outweighs risk. |
| Fetal Monitoring | Monitor intraocular pressure (IOP) regularly due to corticosteroid component; watch for signs of secondary infection. In pregnancy, assess fetal growth if used long-term or at high doses. Monitor maternal blood glucose if systemic absorption suspected. |
| Fertility Effects | No specific studies on fertility effects. Corticosteroids may affect hypothalamic-pituitary-adrenal axis, but topical ophthalmic use is unlikely to impact fertility significantly. |
| Clinical Pearls | VASOCIDIN (hydrocortisone 10 mg/mL + neomycin sulfate 3.5 mg/mL + polymyxin B sulfate 10,000 units/mL) ophthalmic suspension is a topical corticosteroid-antibiotic combination for ocular inflammation with bacterial infection or risk. Do not use for viral, fungal, or mycobacterial infections. Prolonged use may lead to elevated intraocular pressure (IOP), cataract formation, secondary infections, and delayed wound healing. Monitor IOP regularly, especially in patients with glaucoma. Avoid wearing contact lenses during treatment. Shake well before each use; avoid touching dropper tip to any surface to prevent contamination. Not for injection or oral use. |
| Patient Advice | Shake the bottle vigorously before each use. · Instill 1-2 drops into the affected eye(s) as directed, usually every 1-4 hours depending on severity. · Do not touch the dropper tip to your eye or any surface to avoid contamination. · Remove contact lenses before use; do not wear while using this medication. · If you use other eye drops, wait at least 5 minutes between applications. · Report any signs of worsening infection, eye pain, vision changes, or if symptoms persist beyond a few days. · Do not use this medication for conditions other than prescribed; it is for short-term use only. · Keep the bottle tightly closed when not in use and store at room temperature away from moisture and heat. |